VolitionRXVNRX
About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Employees: 110
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
115% more capital invested
Capital invested by funds: $4.89M [Q2] → $10.5M (+$5.64M) [Q3]
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
9.28% more ownership
Funds ownership: 9.75% [Q2] → 19.03% (+9.28%) [Q3]
19% less funds holding
Funds holding: 27 [Q2] → 22 (-5) [Q3]
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
D. Boral Capital Jason Kolbert 36% 1-year accuracy 38 / 107 met price target | 635%upside $5 | Buy Maintained | 15 Nov 2024 |
EF Hutton Jason Kolbert 36% 1-year accuracy 38 / 107 met price target | 635%upside $5 | Buy Maintained | 1 Nov 2024 |
EF Hutton Tim Moore 33% 1-year accuracy 13 / 39 met price target | 635%upside $5 | Buy Assumed | 26 Aug 2024 |
Financial journalist opinion
Based on 5 articles about VNRX published over the past 30 days
